Abstract
THE growing evidence of the effectiveness of uterine artery embolization (UAE) has led to its acceptance as a treatment for fibroids in many centers around the world. It has created considerable interest among women and in the mainstream press. Gynecologists are becoming aware of the procedure and many are regularly referring patients for evaluation and treatment. The published case series are uniformly positive in their assessment of outcome (1–10). In this issue of JVIR, Pelage and coworkers (11) report their experience with a newer embolic agent, trisacryl gelatin microspheres (Embospheres; Biosphere Medical, Rockland, MA), with results similar to those of earlier reports.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
